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Protease nexin-1 prevents growth of
human B cell lymphoma via inhibition of
sonic hedgehog signaling
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Diffuse large B cell lymphoma (DLBCL) is the most
common non-Hodgkin lymphoma (NHL) in adults1. One-
third to half of people with DLBCL is not cured despite
substantial therapy advance2. The variability of outcome is
associated with prognostic scoring system such as the
International Prognostic Index (IPI), which focus on
biological features of the host and of the neoplastic cells1.
However, considerable recent data suggest lymphoma
microenvironment contributes to prognosis by affecting
lymphoma cell survival and angiogenesis3–5. For example,
gene chip from DLBCL tissues revealed a stromal sig-
nature that associated with favorable prognosis5. This
signature is predominantly composed of genes encoding
extracellular matrix (ECM) components and modiﬁers
such as laminin, ﬁbronectin, and collagen5. Those with a
stromal 2 pattern encoding angiogenesis-related genes are
unfavorable5.
Matrix metalloproteinase-9 (MMP-9) regulates tumor
microenvironment by degrading ECM and collagen type-
IV, disrupting the physical barrier to facilitate cancer cell
invasion6. MMP9 is over-expressed in high-grade NHL,
associated with an unfavorable prognosis in DLBCL6,7.
SB3CT, a potent gelatinase inhibitor against MMP-9/
MMP-2, inhibits angiogenesis, prevents formation of
lymphatic vessels, and reduces the spread of lymphoma
cells in a mouse T cell lymphoma model8. However, little
is known of how MMP-9 regulates the lymphoma
microenvironment.
In a prior study through a proteomic approach, we
showed that protease nexin-1 (PN-1) is susceptible to
MMP-9-mediated degradation in the prostate cancer
microenvironment9. PN-1, a 43 kDa serine protease
inhibitor, prevents several key micro-environmental pro-
teases including urokinase plasminogen activator (uPA,
encoded by PLAU), tissue plasminogen activator (tPA),
thrombin, and plasmin10,11. High levels of MMP-9 and
uPA are associated with disease progression and an
unfavorable prognosis in several human solid cancers11.
Although deregulation of PN-1 occurs in several solid
cancers, the role if any, of PN-1 in hematological cancers
is unknown. The coincidence of MMP9 and PLAU gene
found in the DLBCL stromal 1 signature5 suggests a
possible link between expression of these genes and the
lymphoma microenvironment.
First, low levels of PN-1 were found in lymphoid tissues
(lymph nodes and spleen) inﬁltrated with DLBCL cells
compared with controls (Fig. 1a). High transcript levels of
MMP9 were found in the DLBLC-inﬁltrated tissues,
consistent with prior reports and gene chip data5. In
contrast, PN1 transcript levels in DLBCL-inﬁltrated tis-
sues were signiﬁcantly lower compared with reactive
lymph nodes (Fig. 1b). Interestingly, in contrast to the low
transcript levels of PN1 in the DLBCL-inﬁltrated bone
marrow, bone marrow from subjects with DLBCL without
bone marrow involvement had high levels of PN1 tran-
scripts (Fig. 1c). Thus, PN-1 levels appear reduced in B
cell lymphoma.
To determine how PN-1 affects the biology of lym-
phoma cells, we examined endogenous PN1 transcript
levels in a number of human B cell lymphoma cell lines
(Figure S1A). In contrast to low PN1 expression, MMP9
transcript levels were highest in Raji cells (derived from
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Burkitt lymphoma) (Figure S1B). In contrast, Wsunhl and
Jeko cells (derived from follicular lymphoma and mantle
cell lymphoma respectively) with lower MMP9 transcript
levels than Raji cells had high levels of PN1 transcripts
(Figure S1B), in keeping with a known regulation of PN-1
being a substrate target of MMP-99,12,13. Adding exo-
genous PN-1 prevented proliferation of Raji cells and A20
cells (a mouse B cell lymphoma cell line) while knock-
down of PN1 expression by siRNA increased proliferation
of these cells (Figs. 1di–ii and S2A). Adding exogenous
PN1 to Raji and A20 cells increased apoptosis determined
by ﬂow cytometry and by the caspase-3 assay (Figs. 1e and
S2B). In contrast, apoptosis decreased in cells where PN1
expression was reduced by siRNA (Fig. 1f).
Next, we developed a syngeneic B cell lymphoma mouse
model by subcutaneous injection of A20 cells into Balb/c
mice. Adding recombinant PN-1 protein (10 μM) to the
Matrigel plug signiﬁcantly delayed lymphoma growth
(Fig. 1gi). Tumor volumes of mice treated with exogenous
PN-1 protein after 12 days were 500mm3 compared with
989mm3 in controls (p < 0.001). Apoptosis rates in the
tumor grafts were examined in situ using a TUNEL assay
and/or immune blotting or immune-histochemistry for
caspase-3 cleavage (Fig. 1gi). Adding PN-1-induced
apoptosis while inhibiting proliferation as evidenced by
markedly increased caspase-3 staining and decreased
Ki67 staining (Fig. 1h).
The SHH-signaling pathway is activated in DLBCL and
contributes to lymphoma cell survival and proliferation14.
Over-expression of PN1 resulted in a reduced transcrip-
tion and protein expression of molecules in the SHH-
signaling pathway including SHH, GLI1, and PTCH1 in
human Raji and mouse A20 cells (Figs. 2a and S2C).
Conversely, PN1 downregulation by siRNA was associated
with increased expression of SHH and GLI1 (Fig. 2b),
indicating PN1 expression inhibits SHH signaling in
lymphoma cells. Here, we compared inhibitory effects of
PN-1 on lymphoma cells with those of the SHH signaling
inhibitor cyclopamine, which irreversibly binds SMO and
inactivates SHH signaling. Raji cells treated with exo-
genous PN1 or 10 μM cyclopamine can both prevent
SHH-signaling transcription (Fig. 2c). There was more
inhibition of SHH signaling when cells were treated with
PN1 plasmid transfection and cyclopamine compared
with cyclopamine alone (Fig. 2d). Increasing concentra-
tions of cyclopamine produced a dose-dependent
decrease of mRNA levels of GLI1 and SHH (Figure
S3A). Adding PN-1 recombinant protein had a similar
effect as cyclopamine in reducing GLI1 and SHH
expression in A20 cells (Figure S3B–C). At 48 and 72 h,
cyclopamine was a stronger inhibitor of proliferation,
whereas effects on apoptosis were similar (Fig. 2e). We
also determined SHH and GLI1 transcript levels in A20
cells treated with recombinant PN-1. Levels of SHH and
GLI1 transcripts were reduced by 96.8 and 86.8% after
treatment with 100 ng/ml recombinant PN-1 (Fig. 2f).
Apoptosis of A20 cells induced by recombinant PN-1 was
similar to that induced by cyclopamine (Figure S3D).
SHH protein strongly expresses in DLBCL cells but not
in less aggressive lymphomas, CLL and normal germinal
center B cells14. We next studied the activation state of
SHH signaling in vivo in a syngeneic B cell lymphoma
model described in Fig. 1g. Twelve days of PN-1 treat-
ment markedly reduced mRNA levels of GLI1 and SHH
(Fig. 2gi). Angiogenesis is associated with aggressive
subtypes of B cell lymphomas15. To determine the impact
of PN-1 on angiogenesis, we used CD31 staining in mice
grafted with A20 lymphoma cells. Lymphomas grown
with exogenous PN-1 recombination protein had lower
vascular density (Figs. 2h and S4). Residual blood vessels
had larger diameters than controls. There was also less
in situ protein levels of SHH-signaling molecules in tis-
sues treated with PN-1 shown by immune blotting of
whole tissue lysates and by immune-histochemistry (Fig.
2gii–h). Thus, PN-1 appears having an anti-angiogenic
role in B cell lymphoma.
Interestingly, MMP9 expression and SHH signaling are
both known of regulating the growth and survival of
Fig. 1 The expression pattern of PN-1 in DLBCL and its functional impact on lymphoma cell proliferation and apoptosis. a Immune histo-
chemical staining (brown) of PN-1 in spleen and lymph nodes from normals or inﬁltrated with DLBCL cells. Blue stain represents haemotoxylin
nuclear staining. b Quantitative real-time PCR for the expression of MMP9 and PN1 in lymph nodes hyperplasia (LN) and DLBCL. N= 6, ***P < 0.001.
Student's t test was performed for statistical signiﬁcance. c DAB staining of PN-1 (brown, panel i) and relative expression score (ii) in controls with a
normal bone marrow (N= 9), persons with lymphoma with an involved (N= 7) or uninvolved bone marrow (N= 6). One-way ANOVA performed for
statistical signiﬁcance. d Proliferation of Raji cells (2 × 106) was analyzed by using CCK-8 assays at 24, 48, 72, and 96 h after transfection with 2 μg of
pcDNA3-PN1 or control plasmid (i) or followed by treatment of 40 pmol siRNA PN1 (siPN1) or control scrambled siRNA (siNEG) (N= 3; ttest *P < 0.05;
**P < 0.01; ***P < 0.001); e Apoptosis analysis was determined by Annexin-PI assay (i) and immune-blotting of cleavage of caspase-3 (15-kDa active
band) (ii) in Raji cells transfected with 2 μg of pcDNA3-PN1 or control plasmid (N= 4; ttest **P < 0.01); f Raji cells transfected with siRNA PN1 (siPN1) or
control siRNA (siNEG) were assayed for apoptosis (N= 3; t test *P < 0.05); g Subcutaneous tumor volumes from Balb/c mice implanted with A20 cells
(1 × 106) mixed with Matrigel with or without PN-1 recombinant protein (10 μM). Subcutaneous tumor growth curve (i) (N= 5; ttest, **P < 0.01; ***P <
0.001) and tumor volumes (ii); immune-blotting detecting caspase-3 cleavage (iii); h A20 xenografts with or without pre-treatment with PN-1 (10 μM)
recombinant protein, DAB-stained (brown) for caspase-3 and Ki67. Blue stain represents hematoxylin nuclear staining. (i) in situ apoptotic assay using
TUNEL. Positive cells (red stain) were counted from three microscopic ﬁelds and plotted (N= 4, t test, **P < 0.01). Nuclei are blue stained
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diverse NHL cells5,7,15. Our data suggest that PN1 might
be a key player who connects these two important
molecules. We subcutaneously injected Raji cells into
NOD/SCID mice. Adding 7.5 μM SB3CT to the Matrigel
plug inhibited growth of the Raji cells compared with
control Matrigel plugs (Fig. 2i–i). At 24 d the tumor
volume of treated mice were 260mm3 versus 550 mm3 in
controls (p < 0.05; Fig. 2i–i). SB3CT treatment resulted in
increased levels of PN-1 and reduced levels of SHH and
GLI (Fig. 2i–ii). These data suggest that PN-1 inhibition of
SHH signaling is governed by MMP-9, presumably
attributed to increased stability of PN-1 upon chemical
inhibition of MMP-9 activity by SB3CT.
Finally, because of the heterogeneity of DLBCL, we
determined the levels of SHH and PN-1 in normal lymph
nodes, reactive lymph nodes and lymph nodes inﬁltrated
with DLBCL cells. SHH protein localizes predominantly
to the cytoplasm of the lymphoma cells but sparse in the
microenvironment (Fig. 2j). PN-1 expression was evident
in the stroma and vessels of normal and reactive lymph
nodes but less so in lymph nodes inﬁltrated by DLBCL
cells (Fig. 2j). There was an inverse correlation between
PN-1 and SHH levels in tissues inﬁltrated by DLBCL cells
(r=−0.42; p= 0.0034). These data suggest lymph nodes
inﬁltrated by DLBCL cells had variable expression of both
proteins, whereas normal lymph nodes were less variable.
This ﬁnding is not surprising in view of the considerable
heterogeneity of DLBCL. Gene chip analyses from 414
newly diagnosed cases of DLBCL revealed MMP9 and
PLAU in the stromal signature, suggesting genes encoding
ECM proteases such asMMP9 might play critical roles on
progression of B cell lymphoma5. However, considerable
data suggest a striking heterogeneity in gene expression
proﬁles and clinical outcomes of DLBCL, posing a chal-
lenge for clinical management. Consequently, molecular
regulation of MMP-9, PN-1, and SHH may be different
across DLBCL subtypes. SHH is produced by dendritic
cells in the germinal center (GC) protecting germinal
center B cell from apoptosis15. DLBCL cells secrete and
respond to endogenous SHH ligands, implicating an
autocrine SHH-signaling loop14. Our data from immune
histo-chemical staining supports this concept.
Taken together, we present data supporting a new
pathway by which PN1 expression regulates lymphoma
cell survival by inhibiting SHH signaling, an important
survival signaling in the growth of B cell lymphomas. PN-
1 regulates SHH signaling by reducing SHH transcripts
and downstream effectors and by inhibiting angiogenesis.
Such a regulation is also reﬂected by the inverse corre-
lation between PN-1 and SHH proteins demonstrated in
human DLBCL tissue microarray samples. The crosstalk
between MMP-9, PN-1, and SHH signaling supports an
inhibitory role of PN-1 in B cell lymphoma progression.
MMP-9 and PN-1 may serve as potential molecular tar-
gets for combination therapies in DLBCL, in particular for
those lymphomas with high expression of MMP9.
Acknowledgements
DX and YD are funded by Natural Science Foundation of China (81372326;
81273252). JFA and RPG acknowledge support from the National Institute of
Health Research (NIHR) Biomedical Research Centre funding scheme.
Author details
1Department of Haematology, Tongji Hospital, Tongji Medical College,
Huazhong University of Science and Technology, Hubei, China. 2Department
of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University
of Science and Technology, Hubei, China. 3Gray Institute of Radiation
Oncology and Biology, Medical Science Division, University of Oxford, Oxford,
UK. 4Department of Haematology, Hammersmith Hospital, Imperial College
Healthcare NHS Trust, Imperial College London, Du Cane road, London W12
0HS, UK
Conﬂict of interest
The authors declare that they have no conﬂict of interest.
Fig. 2 PN-1 inhibits SHH signaling and angiogenesis of B cell lymphoma. a Real-time PCR (i–ii) and immunoblotting (iii) were applied to
determine the expression of PN1, GLI1, PTCH1, and SMO in Raji cells transfected with a PN1 expression plasmid or empty vector (2 μg) for 24 h (N= 5,
ttest, *P < 0.05; ***P < 0.001). b Raji cells transfected with 40 pmol siRNA PN1 (siPN1) or control siRNA (siNEG) were measured for PN1, SHH, or GLI1
transcript levels using qRT-PCR (i) and protein levels by immune-blotting (ii) (N= 5; t test, *P < 0.05; **P < 0.01; ***P < 0.001). c Transcriptional levels of
SHH (i), PTCH1 (ii) in Raji cells transfected with pcDNA3-PN1 plasmid (2 μg) or treated with a SMO inhibitor cyclopamine (20 μM) or both for 24 h (N=
6; one-way ANOVA; *P < 0.05; **P < 0.01; ***P < 0.001). d Immune-blotting of SHH-signaling pathway molecules and PN-1 from Raji cells treated as
indicated above. e Cell proliferation (i) was analyzed by CCK-8 proliferation assay after 48 and 72 h culture of cells treated with PN1 transfection (2 μg)
or cyclopamine (20 μM); apoptosis (ii) was determined by ﬂow cytometry via Annexin-PI staining at 24 h as indicated above (N= 4; one-way ANOVA
*P < 0.05; **P < 0.01; ***P < 0.001). f A20 cells (2 × 106) were treated with mouse PN-1 recombinant protein at 50 or 100 ng/ml and mRNA transcripts
SHH (i), GLI1 (ii), and PN1(iii) were measured by q-RT-PCR (N= 3; one-way ANOVA *P < 0.05; ***P < 0.001). Immune-blotting of PN-1 protein was
performed using A20 cell conditioned medium (iv); g real-time PCR (i) for PN1, SHH, and GLI1 in A20 xenografts with or without PN-1 (10 μM) (N= 5; t
test, **P < 0.01; ***P < 0.001); A20 xenografts with or without PN-1 (10 μM) were blotted via immune blotting (ii). h immune-histochemistry (brown)
for SHH-signaling cascades and PN-1 in A20 xenograft tumor. DAB-stained for the angiogenesis marker CD31 (brown). Blue stain is hemotoxylin
nuclear staining; i(i) Subcutaneous tumor volumes from NOD/SCID mice implanted with Raji cells (5 × 106) mixed with PBS or Matrigel with or
without SB3CT (7.5 μM) were measured and plotted (N= 3; t test *P < 0.05). (ii) Immune blots of PN-1, SHH, and GLI1 in Raji Nod/SCID xenografts with
or without SB3CT (7.5 μM). j DAB staining of PN-1 and SHH in human lymphoid tissues. Measurement of staining intensity compared with lymph
nodes from normal (N= 10), lymph node reactive hyperplasia (N= 13), or DLBCL-inﬁltrated lymph nodes (N= 24). One-way ANOVA performed.
Correlation between PN-1 and SHH calculated using Spearman r value
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